by lythamcorp | Jan 6, 2025 | ChromaDex News, Consumer
LOS ANGELES – ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025...
by lythamcorp | Jan 6, 2025 | NAYA News
PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 — NAYA Biosciences (“NAYA”)...
by lythamcorp | Dec 27, 2024 | Energy, Greenfire News, Greenfire Resources
Calgary, Alberta–(December 27, 2024) – Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) (“Greenfire” or the “Issuer”) today announced that it has commenced a change of control offer (the “Change of Control Offer”)...
by lythamcorp | Dec 24, 2024 | Energy, Greenfire News, Greenfire Resources
Calgary, Alberta–(December 23, 2024) – Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) (“Greenfire” or the “Company”), today announced a reconstitution of Greenfire’s Board of Directors (the “Board”), the...
by lythamcorp | Dec 24, 2024 | PolyPid, PolyPid News
630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application (“NDA”) for D-PLEX100 under Fast Track and...